Citius Oncology CTOR Estimates

NASDAQ CTOR
$0.94 +0.01 (+1.17%)
As of: Sep 9, 2026 · 3:59 PM EDT
Analyst Estimates

Citius Oncology, Inc. Revenue Estimates

Periods 24
Next Period Q1 25
Consensus 0.00

Analysts expect Citius Oncology, Inc. to report revenue of 0.00 for Q1 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 26, came in at 1.49 M, a 38.3% miss against the 2.41 M consensus.

Metric Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.000.000.003.94 M1.67 M1.49 M-------
High Estimate 0.005.90 M0.000.004.28 M8.03 M2.53 M6.55 M14.83 M20.92 M28.98 M25.62 M36.50 M41.84 M
Low Estimate 0.005.24 M0.000.003.99 M6.91 M2.30 M5.38 M13.11 M19.67 M25.56 M22.04 M31.51 M34.92 M
Consensus Estimate 0.005.57 M0.000.004.14 M7.47 M2.41 M5.97 M13.97 M20.29 M27.27 M23.83 M34.00 M38.38 M
Analyst Estimates

Citius Oncology, Inc. Earnings Per Share (EPS) Estimates

Periods 24
Next Period Q4 26
Consensus -0.20

Analysts expect Citius Oncology, Inc. to report earnings per share of -0.20 for Q4 26, against a range of -0.22 to -0.18. The most recent reported quarter, Q3 26, came in at -0.08, a 14.3% miss against the -0.07 consensus.

Metric Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.09-0.11-0.08-0.06-0.06-0.27-0.08--------
High Estimate -0.05-0.08-0.14-0.06-0.04-0.01-0.07-0.180.000.04-0.04-0.100.140.180.17
Low Estimate -0.07-0.10-0.16-0.06-0.04-0.01-0.07-0.220.000.04-0.04-0.120.120.140.15
Consensus Estimate -0.06-0.09-0.15-0.06-0.04-0.01-0.07-0.200.000.04-0.04-0.110.130.160.16